MARCOS GONZÁLEZ DÍAZ-rekin lankidetzan egindako argitalpenak (44)

2017

  1. Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma

    Leukemia, Vol. 31, Núm. 10, pp. 2094-2103

2016

  1. Microvesicles from Mesenchymal Stromal Cells Are Involved in HPC-Microenvironment Crosstalk in Myelodysplastic Patients

    PLoS ONE, Vol. 11, Núm. 2

2014

  1. Late differentiation syndrome in acute promyelocytic leukemia: A challenging diagnosis

    Hematology Reports, Vol. 6, Núm. 4, pp. 75-77

  2. Role of minimal residual disease and chimerism after reduced-intensity and myeloablative allo-transplantation in acute myeloid leukemia and high-risk myelodysplastic syndrome

    Leukemia Research, Vol. 38, Núm. 5, pp. 551-556

2012

  1. Impaired expression of DICER, DROSHA, SBDS and some microRNAs in mesenchymal stromal cells from myelodysplastic syndrome patients

    Haematologica, Vol. 97, Núm. 8, pp. 1218-1224

2009

  1. Multitargeted sequential therapy with MK-0457 and dasatinib followed by stem cell transplantation for T315I mutated chronic myeloid leukemia

    Leukemia Research

2002

  1. Chimerism and minimal residual disease monitoring after reduced intensity conditioning (RIC) allogeneic transplantation

    Leukemia, Vol. 16, Núm. 8, pp. 1423-1431

2001

  1. Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification

    Blood, Vol. 98, Núm. 6, pp. 1746-1751

2000

  1. Allogeneic peripheral stem cell transplantation in a case of hereditary sideroblastic anaemia

    British Journal of Haematology, Vol. 109, Núm. 3, pp. 658-660

  2. Cerebral toxoplasmosis and Guillain-Barre syndrome after allogeneic peripheral stem cell transplantation

    Transplant Infectious Disease, Vol. 2, Núm. 3, pp. 145-149

1999

  1. Clinical significance of CD34+ cell dose in long-term engraftment following autologous peripheral blood stem cell transplantation

    Bone Marrow Transplantation, Vol. 24, Núm. 12, pp. 1279-1283

  2. Detection of abnormalities in B-cell differentiation pattern is a useful tool to predict relapse in precursor-B-ALL

    British Journal of Haematology, Vol. 104, Núm. 4, pp. 695-705

1998

  1. Minimal number of circulating CD34+ cells to ensure successful leukapheresis and engraftment in autologous peripheral blood progenitor cell transplantation

    Transfusion, Vol. 38, Núm. 4, pp. 385-391

  2. Recuperación inmune tras trasplante autólogo de células progenitoras hemopoyéticas. Comparación entre células progenitoras de sangre periférica y de médula ósea

    Medicina Clinica, Vol. 110, Núm. 20, pp. 768-773

1997

  1. Alternating mini-BEAM/ESHAP as salvage therapy for refractory non-Hodgkin's lymphomas

    Annals of Hematology, Vol. 74, Núm. 2, pp. 79-82

  2. BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: Analysis of efficacy, toxicity and prognostic factors

    Bone Marrow Transplantation, Vol. 20, Núm. 6, pp. 451-458

  3. Minimal number of circulating CD34+ cells to assure successful leukapheresis and engraftment in peripheral blood progenitor cell transplantation

    Infusionstherapie und Transfusionsmedizin, Vol. 24, Núm. 4, pp. 234

1996

  1. A randomized study comparing the effect of GM-CSF and G-CSF on immune reconstitution after autologous bone marrow transplantation

    British Journal of Haematology, Vol. 94, Núm. 1, pp. 140-147

1995

  1. Phenotypic analysis of CD34 subpopulations in normal human bone marrow and its application for the detection of minimal residual disease

    Leukemia, Vol. 9, Núm. 11, pp. 1896-1901

1994

  1. The phenotype of L-CFU and its correlation with the immunological characteristics of the blast cell population in AML

    Annals of Hematology, Vol. 68, Núm. 5, pp. 233-236